SRTSHIGH SIGNALFINANCIAL10-K

Sensus Healthcare experienced a substantial revenue decline alongside significantly reduced gross profit margins, while dramatically increasing R&D investments.

The company faces a challenging financial period with revenue dropping over one-third year-over-year, indicating potential market headwinds or execution issues. The substantial increase in R&D spending suggests management is investing heavily in future product development, but this comes at a time when core business performance is weakening, creating near-term pressure on profitability.

Comparing 2026-03-04 vs 2025-03-05View on EDGAR →
FINANCIAL ANALYSIS

The financial picture shows a company under significant operational stress, with revenue declining meaningfully to $27.5M while gross profit was substantially reduced to $11.9M, indicating compressed margins. R&D expenses nearly doubled to $7.8M, reflecting heavy investment in development activities. The balance sheet shows signs of operational challenges with accounts receivable dropping sharply from $19.7M to $6.0M, while inventory increased to $14.6M, suggesting potential collection improvements but possible demand softness.

FINANCIAL STATEMENT CHANGES
R&D Expense
P&L
+84.5%
$4.2M→$7.8M

R&D investment increased 84.5% — signals commitment to future product development, though near-term margin impact.

Accounts Receivable
Balance Sheet
-69.4%
$19.7M→$6.0M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Gross Profit
P&L
-51.4%
$24.4M→$11.9M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Inventory
Balance Sheet
+44.2%
$10.1M→$14.6M

Inventory surged 44.2% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

Revenue
P&L
-34.3%
$41.8M→$27.5M

Revenue declined 34.3% — significant demand weakness or market share loss warrants investigation.

Capital Expenditure
Cash Flow
-29%
$276K→$196K

Capex reduced 29% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Liabilities
Balance Sheet
-22%
$6.3M→$4.9M

Liabilities reduced 22% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-19.8%
$5.9M→$4.7M

Current liabilities reduced — improved short-term financial position and working capital health.

Current Assets
Balance Sheet
-19.1%
$56.7M→$45.9M

Current assets declined 19.1% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-14.7%
$62.2M→$53.0M

Total assets contracted 14.7% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2026-03-04
PRIOR — 2025-03-05
ADDED
As of February 24, 2026, there were 16,462,059 shares of the registrant s common stock outstanding.
and China, including the concentration of sales to one particular customer in the U.S.; the development by others of new products, treatments, or technologies that render our technology partially or wholly obsolete; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries, including ongoing geopolitical tensions between the U.S.
To date, geopolitical uncertainties other than those relating to China have not had any significant impact on our business, but we continue to monitor developments and will address them in future disclosures, if applicable.
and Sensus Healthcare Services, LLC, unless the context otherwise indicates, Sensus, we, us, our, or the Company ) is a medical device company committed to providing highly effective, non-invasive treatments for non-melanoma skin cancer (NMSC) and post-surgical keloid scar prevention.
To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions of close to one-million patients around the world.
+7 more — sign up free →
REMOVED
As of February 12, 2025, there were 16,495,396 shares of the registrant s common stock outstanding.
To date, the Middle East conflict, the Russian invasion of Ukraine, and other geopolitical uncertainties have not had any significant impact on our business, but we continue to monitor developments and will address them in future disclosures, if applicable.
and Sensus Healthcare Services, LLC, unless the context otherwise indicates, Sensus, we, us, our, or the Company ) is a medical device company committed to providing highly effective, non-invasive, and cost-effective treatments for both oncological and non-oncological skin conditions.
To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in hundreds of thousands of patients around the world.
In February 2024, the Company formed Sensus Healthcare Services, LLC, a wholly-owned subsidiary that provides operational healthcare services to dermatology clinics.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →